Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
Portfolio Pulse from Benzinga Newsdesk
Genentech's Evrysdi shows promising two-year data for treating Spinal Muscular Atrophy (SMA) in children, with most achieving key mobility milestones. The therapy is non-invasive and approved in over 100 countries.
October 14, 2024 | 6:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genentech's Evrysdi demonstrates positive two-year data for treating SMA in children, achieving key mobility milestones. This strengthens its market position as a non-invasive therapy approved in over 100 countries.
The positive data on Evrysdi's efficacy and safety in treating SMA, especially in children treated early, enhances Genentech's product portfolio. As the only non-invasive SMA therapy, its approval in over 100 countries and treatment of over 16,000 people globally positions it strongly in the market, likely boosting investor confidence and stock performance.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90